These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 11383906)

  • 1. GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide.
    Attanasio R; Barausse M; Cozzi R
    J Endocrinol Invest; 2001 Apr; 24(4):209-16. PubMed ID: 11383906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly.
    Cozzi R; Dallabonzana D; Attanasio R; Barausse M; Oppizzi G
    Eur J Endocrinol; 1999 Sep; 141(3):267-71. PubMed ID: 10474124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lanreotide 60 mg, a longer-acting somatostatin analog: tumor shrinkage and hormonal normalization in acromegaly.
    Cozzi R; Barausse M; Sberna M; Lodrini A; Franzini A; Lasio G; Attanasio R
    Pituitary; 2000 Dec; 3(4):231-8. PubMed ID: 11788011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly.
    Attanasio R; Baldelli R; Pivonello R; Grottoli S; Bocca L; Gasco V; Giusti M; Tamburrano G; Colao A; Cozzi R
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5258-65. PubMed ID: 14602759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly.
    Ambrosio MR; Franceschetti P; Bondanelli M; Doga M; Maffei P; Baldelli R; Tamburrano G; Sicolo N; Giustina A; degli Uberti EC
    Metabolism; 2002 Mar; 51(3):387-93. PubMed ID: 11887179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of a two-year treatment with slow release lanreotide in acromegaly.
    Cannavò S; Squadrito S; Curtò L; Almoto B; Vieni A; Trimarchi F
    Horm Metab Res; 2000 Jun; 32(6):224-9. PubMed ID: 10898551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg).
    Baldelli R; Colao A; Razzore P; Jaffrain-Rea ML; Marzullo P; Ciccarelli E; Ferretti E; Ferone D; Gaia D; Camanni F; Lombardi G; Tamburrano G
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4099-103. PubMed ID: 11095439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide.
    Suliman M; Jenkins R; Ross R; Powell T; Battersby R; Cullen DR
    J Endocrinol Invest; 1999 Jun; 22(6):409-18. PubMed ID: 10435849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients.
    Verhelst JA; Pedroncelli AM; Abs R; Montini M; Vandeweghe MV; Albani G; Maiter D; Pagani MD; Legros JJ; Gianola D; Bex M; Poppe K; Mockel J; Pagani G
    Eur J Endocrinol; 2000 Nov; 143(5):577-84. PubMed ID: 11078980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide.
    Caron P; Morange-Ramos I; Cogne M; Jaquet P
    J Clin Endocrinol Metab; 1997 Jan; 82(1):18-22. PubMed ID: 8989225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
    Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly.
    Colao A; Marzullo P; Ferone D; Marinò V; Pivonello R; Di Somma C; Di Sarno A; Giaccio A; Lombardi G
    J Endocrinol Invest; 1999 Jan; 22(1):40-7. PubMed ID: 10090136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
    Colao A; Pivonello R; Cappabianca P; Briganti F; Tortora F; Auriemma RS; De Martino MC; Marzullo P; Lombardi G
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study.
    Colao A; Auriemma RS; Galdiero M; Lombardi G; Pivonello R
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3746-56. PubMed ID: 19622615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M; Gussoni G; Cuttica CM; Giordano G
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly.
    Chanson P; Leselbaum A; Blumberg J; Schaison G
    Pituitary; 2000 May; 2(4):269-76. PubMed ID: 11081148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.
    Cozzi R; Attanasio R; Lodrini S; Lasio G
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):209-15. PubMed ID: 15272916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly.
    Andries M; Glintborg D; Kvistborg A; Hagen C; Andersen M
    Clin Endocrinol (Oxf); 2008 Mar; 68(3):473-80. PubMed ID: 17941902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
    Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
    J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly.
    Tutuncu Y; Berker D; Isik S; Ozuguz U; Akbaba G; Kucukler FK; Aydin Y; Guler S
    Pituitary; 2012 Sep; 15(3):398-404. PubMed ID: 21863263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.